Derivatives Designated as Cash Flow Hedging Instruments
BioMarin Pharmaceuticals·Products & Services·1 segment·Rolls up to OCI Cash Flow Hedge Reclassification, Before Tax
Breakdown
Segments
Net product revenuesView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net product revenues | $3.37M | $3.37M | $9.09M | $12.55M | -$2.06M | -$10.64M | -$20.45M | -$12.41M |
| Total | — | — | — | — | — | — | — | — |